TY - JOUR
T1 - Cognition in patients with neuromyelitis optica spectrum disorders
T2 - A prospective multicentre study of 217 patients (CogniNMO-Study)
AU - Hümmert, Martin W.
AU - Stern, Carlotta
AU - Paul, Friedemann
AU - Duchow, Ankelien
AU - Bellmann-Strobl, Judith
AU - Ayzenberg, Ilya
AU - Schwake, Carolin
AU - Kleiter, Ingo
AU - Hellwig, Kerstin
AU - Jarius, Sven
AU - Wildemann, Brigitte
AU - Senel, Makbule
AU - Berthele, Achim
AU - Giglhuber, Katrin
AU - Luessi, Felix
AU - Grothe, Matthias
AU - Klotz, Luisa
AU - Schülke, Rasmus
AU - Gingele, Stefan
AU - Faiss, Jürgen H.
AU - Walter, Annette
AU - Warnke, Clemens
AU - Then Bergh, Florian
AU - Aktas, Orhan
AU - Ringelstein, Marius
AU - Stellmann, Jan Patrick
AU - Häußler, Vivien
AU - Havla, Joachim
AU - Pellkofer, Hannah
AU - Kümpfel, Tania
AU - Kopp, Bruno
AU - Trebst, Corinna
N1 - Publisher Copyright:
© The Author(s), 2023.
PY - 2023/6
Y1 - 2023/6
N2 - Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD). Objective: To assess cognitive performance and changes over time in NMOSD. Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data (N = 157). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model. Results: NMOSD patients were impaired in SDMT (p = 0.007), MuSIC semantic fluency (p < 0.001), and MuSIC congruent speed (p < 0.001). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability (pBon < 0.05). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD. Conclusions: A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.
AB - Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD). Objective: To assess cognitive performance and changes over time in NMOSD. Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data (N = 157). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model. Results: NMOSD patients were impaired in SDMT (p = 0.007), MuSIC semantic fluency (p < 0.001), and MuSIC congruent speed (p < 0.001). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability (pBon < 0.05). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD. Conclusions: A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.
KW - Neuromyelitis optica spectrum disorders
KW - cognition
KW - cognitive neuropsychology
KW - neuroimmunology
UR - http://www.scopus.com/inward/record.url?scp=85152080920&partnerID=8YFLogxK
U2 - 10.1177/13524585231151212
DO - 10.1177/13524585231151212
M3 - Article
C2 - 36786424
AN - SCOPUS:85152080920
SN - 1352-4585
VL - 29
SP - 819
EP - 831
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 7
ER -